Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07359014 | Recruiting

• 1 other identifier: 2025-0650
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.

Conditions

Relapse Multiple Myeloma

Keywords

CAR-T therapy

Outcome Measures

Primary Outcomes (2)

• The incidence of adverse events

  The incidence of adverse events and abnormal laboratory findings that are "possibly" or "definitely" related to the study treatment, occurring at any time from the start of monitoring until Week 24, including dose-limiting toxicity (DLT).

  up to 24 weeks

• Primary implant endpoint

  The survival time of CAR-T cells in vivo is defined as the "engraftment endpoint." PCR detection of CAR-T cell DNA sequences begins 24 hours post-infusion at scheduled follow-up time points and continues until any two consecutive tests yield negative results, at which point the "engraftment endpoint" is recorded.

  up to 2 years

Secondary Outcomes (7)

• complete response (CR), very good partial response (VGPR), and partial response (PR)

  up to 2 years

• Overall survival

  up to 2 years

• Progression-free survival

  up to 2 years

• Detection and quantification of CD19/BCMA CAR-T cells

  up to 2 years

• Detection and quantification of circulating soluble BCMA

  up to 2 years

Study Arms (1)

Dual CD19/BCMA CAR-T treatment

EXPERIMENTAL

R/R multiple myeloma patients will be treated with novel dual CD19/BCMA CAR-T

Other: Dual CD19/BCMA CAR-T

Interventions

Dual CD19/BCMA CAR-T OTHER

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy

Dual CD19/BCMA CAR-T treatment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Relapsed/refractory multiple myeloma.
• Confirmed by immunohistochemistry (IHC) or flow cytometry of bone marrow samples: plasma cell membrane expression of BCMA is positive (≥30%); no requirement for CD19 positivity rate. All sites must centrally submit bone marrow or plasmacytoma biopsy specimens to the lead site's pathology department or bone marrow/liquid specimens to KingMed Diagnostics (third-party laboratory) for BCMA expression verification.
• Relapsed/refractory patients must meet the following criteria:
• No response or disease progression after 3 cycles of bortezomib (proteasome inhibitor) or lenalidomide therapy No response or disease progression after 3 cycles of prior treatment regimen Interval between last treatment and disease progression \>30 days No current indication for hematopoietic stem cell transplantation (HSCT), or patient refusal of HSCT
• Definition of disease progression follows the 2021 International Myeloma Working Group (IMWG) criteria, meeting at least one of the following:
• Serum M protein ≥ 5 g/L Urine M protein ≥ 200 mg/24 h If serum free light chain (FLC) ratio is abnormal, patient FLC level ≥ 100 mg/L Biopsy-confirmed evaluable plasmacytoma Increased myeloplasmacytic percentage ≥25% (absolute increase ≥10%) Myeloplasm cells constitute ≥30% of total bone marrow cells
• Expected survival \>12 weeks;
• Disease status is evaluable and meets at least one of the following:
• Serum M-protein ≥10 g/L, 24-hour urine M-protein ≥ 200 mg, Serum FLC ≥ 50 mg/L, Plasmacytoma evaluable by imaging or laboratory testing, Bone marrow plasma cell percentage ≥ 30%
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
• Sufficient venous access for apheresis or venipuncture, with no other contraindications to blood cell separation;
• white blood cell (WBC) ≥ 1.5 × 10⁹/L; platelet (PLT) ≥ 45 × 10⁹/L.
• Serum creatinine ≤ 1.5 times the upper limit of normal (ULN).
• Alanine Aminotransferase (ALT) ≤ 2.5 ULN, Aspartate Aminotransferase (AST) ≤ 2.5 ULN.
• All laboratory values within the above ranges must be achieved without ongoing supportive therapy.

You may not qualify if:

• Received systemic therapy such as cyclophosphamide and fludarabine for lymphoma clearance within 2 weeks prior to enrollment or single-cell collection; prior CD19/BCMA CAR-T therapy; or cell or bispecific antibody therapy within 8 weeks prior to treatment.
• Received bendamustine-containing regimens within 6 months prior to treatment.
• Hepatitis C virus (HCV) or Human Immunodeficiency Virus (HIV) positive status; any uncontrolled active infection, including active tuberculosis or Hepatitis B virus (HBV) DNA levels ≥1×10³ copies/mL.
• Active infection within 72 hours prior to treatment initiation; subjects on ongoing prophylactic antibiotics, antifungals, or antivirals are not excluded provided there is no evidence of active infection and the antibiotics are not on the prohibited drug list.
• Renal impairment with serum creatinine \>1.5 times the upper limit of normal (ULN).
• Hepatic impairment with AST and/or ALT \>2.5 times ULN and direct bilirubin \>1.5 times ULN.
• Hyponatremia, serum sodium \< 125 mmol/L.
• Pregnant or lactating women.
• Other serious conditions that may preclude participation in this trial (e.g., central nervous system disorders, severe heart failure, myocardial infarction within the past 6 months, unstable arrhythmia or unstable angina, gastric ulcer, active autoimmune disease, etc.).

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead
• Tongji Hospital: collaborator
• Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University: collaborator
• Jinhua Municipal Central Hospital: collaborator

Study Sites (1)

Xuzhao Zhang

Hangzhou, 310003, China

RECRUITING

Study Officials

• Wenbin Qian, Dr.

  Second Affiliated Hospital, School of Medicine, Zhejiang University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xuzhao Zhang

CONTACT

+86-571-89713679; zxzzju@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: relapsed/refractory multiple myeloma

Study Record Dates

• First Submitted: December 31, 2025
• First Posted: January 22, 2026
• Study Start: November 1, 2025
• Primary Completion (Estimated): October 31, 2027
• Study Completion (Estimated): October 31, 2030
• Last Updated: January 22, 2026

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)